The High Cost of Cancer Drugs and What We Can Do About It

Siddiqui, Mustaqeem; Rajkumar, S. Vincent

doi:10.1016/j.mayocp.2012.07.007

Cited by 221 publications

(217 citation statements)

References 39 publications

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…The development of anticancer drugs is a lengthy and expensive process (1). After a novel compound is identified or designed, preclinical and clinical data from phase I, II and III clinical trials are generated prior to approval.…”

Section: Introductionmentioning

confidence: 99%

Repurposing itraconazole as an anticancer agent

et al. 2017

View full text Add to dashboard Cite

Abstract. Itraconazole, a common anti-fungal agent, has demonstrated potential anticancer activity, including reversing chemoresistance mediated by P-glycoprotein, modulating the signal transduction pathways of Hedgehog, mechanistic target of rapamycin and Wnt/β-catenin in cancer cells, inhibiting angiogenesis and lymphangiogenesis, and possibly interfering with cancer-stromal cell interactions. Clinical trials have suggested the clinical benefits of itraconazole monotherapy for prostate cancer and basal cell carcinoma, as well as the survival advantage of combination chemotherapy for relapsed non-small cell lung, ovarian, triple negative breast, pancreatic and biliary tract cancer. As drug repurposing is cost-effective and timesaving, a review was conducted of preclinical and clinical data focusing on the anticancer activity of itraconazole, and discusses the future directions for repurposing itraconazole as an anticancer agent.

show abstract

Section: Introductionmentioning

confidence: 99%

Repurposing itraconazole as an anticancer agent

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Also in this issue of Mayo Clinic Proceedings, Wittich et al 5 summarize off-label drug use (OLDU), its benefits, and its drawbacks. This article segues nicely with the concepts introduced by Siddiqui and Rajkumar, 4 given the frequency with which OLDU is used in cancer treatment. Wittich et al 5 note that OLDU is a common practice that can benefit patients by expanding access to useful agents approved for other indications, but OLDU also can be overused, often with limited supporting data.…”

mentioning

confidence: 65%

Integrating Value Assessment Into Discussions About the Price of Cancer Drugs

Bunnell

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…29 The absolute cost to society will become increasingly unaffordable if every drug with statistically significant, but clinically unimportant, benefit is approved and will be prescribed/reimbursed. 30 For all new medicines, in addition to efficacy and safety, there should be a focus on value, with measured outcomes.…”

Section: High Drug Costs Should Only Be Considered Acceptable If Imprmentioning

confidence: 99%

“…23,28,29 However, the nature of the disease and the seriousness of a diagnosis of cancer also means that physicians and patients are often willing to pay a high price for treatments, even those associated with only marginal improvements in outcome. 30 Recent research suggests that market exclusivity for most approved tyrosine kinase inhibitors is more than a decade, averaging around 14−15 years. It could be argued that this is more than adequate time for pharmaceutical companies to recoup their investment costs and also make a fair profit, even allowing for the fact that not all of these compounds may be used for the full period of their market exclusivity, due to the approval of newer, more effective agents.…”

mentioning

confidence: 99%

“…35 At the Seventieth World Health Assembly in 2017, a draft resolution proposed by 12 countries, including France and The Netherlands, recommended that a comprehensive technical report be prepared that examines pricing approaches and their impact on the availability and affordability of cancer medicines, including incentives for investment in R&D in cancer and innovation, and financing gaps in R&D. 36 Generic drugs are widely used in oncology; however, the prices of many of these drugs are high compared with those for non-malignant diseases. 30 Furthermore, manipulation of generic drug prices has led to unwarranted price rises of some unbranded generic cancer drugs. For example, in 2013, the price of one pack of a generic busulfan, used to treat leukaemia, rose from £5.20 to £65.22 in England and Wales.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Can we Continue to Afford Access to Cancer Treatment?

Wilking¹,

Lopes²,

Meier³

et al. 2017

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

O ncology is facing a crisis of affordability that is not sustainable. The economic burden of cancer is growing, as a result of the rising cancer incidence and increased survival, alongside growing investment in disease prevention, diagnosis and treatment. The prices of new cancer drugs continue to increase, placing growing pressure on many healthcare systems. The aim of this article is to explore the reasons why the cost of cancer care is increasing, and why this increase may become unsustainable unless changes are made. There are only limited options for future health spending. Finding ways to improve the allocation of existing resources to achieve the best outcomes for patients will be key to achieving sustainability, whilst safeguarding the continued development of new, effective cancer treatments. Currently, too many cancer drugs are approved without robust evidence of value, and spending more on treatments does not necessarily translate to improvements in health. For all new drugs, in addition to efficacy and safety, there should be a focus on value, with measured outcomes and pricing that ensures these drugs are affordable. Fundamental changes to healthcare systems and industry are needed to sustain cancer care and allow continued access to effective and safe treatments for all patients.

show abstract

The High Cost of Cancer Drugs and What We Can Do About It

Cited by 221 publications

References 39 publications

Repurposing itraconazole as an anticancer agent

Repurposing itraconazole as an anticancer agent

Integrating Value Assessment Into Discussions About the Price of Cancer Drugs

Can we Continue to Afford Access to Cancer Treatment?

Contact Info

Product

Resources

About